{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:06:50Z","timestamp":1792782410109,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster","id":[{"id":"https:\/\/ror.org\/01856cw59","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Vitiligo ist eine chronische immunvermittelte Erkrankung, charakterisiert durch depigmentierte Hautareale und assoziiert mit vielf\u00e4ltigen psychischen und somatischen Begleiterkrankungen. F\u00fcr Deutschland existieren nur begrenzt aktuelle Daten zu Pr\u00e4valenz, Komorbidit\u00e4t und Therapieverhalten.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodik<\/jats:title>\n                    <jats:p>In dieser retrospektiven Analyse von Abrechnungsdaten der gesetzlichen Krankenversicherung (GKV) wurden Informationen von Versicherten (\u2265\u202f12\u00a0bzw. \u2265\u202f18\u00a0Jahre) aus 2023 ausgewertet. Pr\u00e4valenzf\u00e4lle wurden anhand des ICD-10-GM-Codes f\u00fcr Vitiligo nach M2Q-Kriterien identifiziert, Inzidenzf\u00e4lle durch fehlendes Auftreten im Vorjahr. Begleiterkrankungen wurden mit einer gematchten Kontrollkohorte verglichen. Die Therapieanalyse erfolgte f\u00fcr die Pr\u00e4valenzkohorte und stratifiziert nach Fachgruppen und nach Ausschluss von Diagnosen mit \u00fcberlappenden Therapien.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      Die GKV-adjustierte Pr\u00e4valenz von Vitiligo lag bei 0,14\u202f%, die Inzidenz bei 0,03\u202f%, beide mit H\u00f6chstwerten in der Altersgruppe 55 bis 64\u00a0Jahre. Von 673 analysierten ICD-10-Diagnosen waren 343 (51,0\u202f%) signifikant h\u00e4ufiger bei Personen mit Vitiligo als bei gematchten Kontrollen (OR: &gt;\u202f1;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\u2264\u20090,05), besonders Autoimmunerkrankungen wie Thyreoiditis, Alopecia areata und Diabetes mellitus Typ\u00a01. In der Pr\u00e4valenzkohorte erhielten nur 22,1\u202f% der Betroffenen eine abgerechnete Behandlung. In der Subkohorte spezialisierter Fachgruppen und Diagnosen ohne \u00fcberlappende Therapien wurden 8,2\u202f% behandelt, davon rund 90\u202f% mit topischen Therapien. Systemische Glukokortikoide und UV-Therapien waren selten.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerung<\/jats:title>\n                    <jats:p>Die Analyse zeigt die aktuelle Versorgungssituation von Vitiligo in Deutschland, unterstreicht den systemischen Charakter der Erkrankung und deutet auf eine alarmierende Unterversorgung hin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00105-026-05764-5","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:17:05Z","timestamp":1787581025000},"page":"673-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vitiligo in Deutschland","Vitiligo in Germany"],"prefix":"10.1007","volume":"77","author":[{"given":"Markus","family":"B\u00f6hm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Heuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"5764_CR1","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","volume":"9","author":"J Akl","year":"2024","unstructured":"Akl\u00a0J, Lee\u00a0S, Ju\u00a0HJ et\u00a0al (2024) Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health 9:e386\u2013e396","journal-title":"Lancet Public Health"},{"key":"5764_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00105-024-05312-z","volume":"75","author":"M Augustin","year":"2024","unstructured":"Augustin\u00a0M, Gewiss\u00a0C, Ben-Anaya\u00a0N et\u00a0al (2024) Quality of life, disease burden and healthcare need of patients with vitiligo. Dermatologie (Heidelb) 75:404\u2013411","journal-title":"Dermatologie (Heidelb)"},{"key":"5764_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","volume":"159","author":"K Bibeau","year":"2023","unstructured":"Bibeau\u00a0K, Ezzedine\u00a0K, Harris\u00a0JE et\u00a0al (2023) Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study. JAMA Dermatol 159:1124\u20131128","journal-title":"JAMA Dermatol"},{"key":"5764_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1111\/jdv.18257","volume":"36","author":"K Bibeau","year":"2022","unstructured":"Bibeau\u00a0K, Pandya\u00a0AG, Ezzedine\u00a0K et\u00a0al (2022) Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J\u00a0Eur Acad Dermatol Venereol 36:1831\u20131844","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5764_CR5","first-page":"365","volume":"20","author":"M B\u00f6hm","year":"2022","unstructured":"B\u00f6hm\u00a0M, Schunter\u00a0JA, Fritz\u00a0K et\u00a0al (2022) S1-Leitlinie: Diagnostik und Therapie der Vitiligo. J\u00a0Dtsch Dermatol Ges 20:365\u2013379","journal-title":"J Dtsch Dermatol Ges"},{"key":"5764_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/ddg.15706_g","volume":"23","author":"M B\u00f6hm","year":"2025","unstructured":"B\u00f6hm\u00a0M, Tanew\u00a0A (2025) Vitiligo. J\u00a0Dtsch Dermatol Ges 23:968\u2013987","journal-title":"J Dtsch Dermatol Ges"},{"key":"5764_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020432","volume":"14","author":"H Clemente","year":"2025","unstructured":"Clemente\u00a0H, Muelas\u00a0R, Gracia\u00a0C et\u00a0al (2025) Comorbidities Associated with Vitiligo: Results from the EpiChron Cohort. J\u00a0Clin Med 14:432","journal-title":"J Clin Med"},{"key":"5764_CR8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/jdv.15987","volume":"34","author":"G Dabas","year":"2020","unstructured":"Dabas\u00a0G, Vinay\u00a0K, Parsad\u00a0D et\u00a0al (2020) Psychological disturbances in patients with pigmentary disorders: a cross-sectional study. J\u00a0Eur Acad Dermatol Venereol 34:392\u2013399","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5764_CR9","unstructured":"European Medicines Agency (EMA) (2023) Opzelura (ruxolitinib) \u2013 An overview of Opzelura and why it is authorised in the EU. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/opzelura. Zugegriffen: 16. Apr. 2026"},{"key":"5764_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","volume":"22","author":"K Ezzedine","year":"2021","unstructured":"Ezzedine\u00a0K, Eleftheriadou\u00a0V, Jones\u00a0H et\u00a0al (2021) Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol 22:757\u2013774","journal-title":"Am J Clin Dermatol"},{"key":"5764_CR11","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s13555-025-01451-w","volume":"15","author":"K Ezzedine","year":"2025","unstructured":"Ezzedine\u00a0K, Harris\u00a0JE, Hamzavi\u00a0IH et\u00a0al (2025) Exploring Vitiligo History and Mental Health Burden Among People Within EU5 Countries: Findings from the Global VALIANT Study. Dermatol Ther (Heidelb) 15:2439\u20132453","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5764_CR12","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s13555-023-01001-2","volume":"13","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine\u00a0K, Soliman\u00a0AM, Li\u00a0C et\u00a0al (2023) Comorbidity Burden Among Patients with Vitiligo in the United States: A Large-Scale Retrospective Claims Database Analysis. Dermatol Ther (Heidelb) 13:2265\u20132277","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5764_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185785","volume":"135","author":"K Ezzedine","year":"2025","unstructured":"Ezzedine\u00a0K, Tannous\u00a0R, Pearson\u00a0TF et\u00a0al (2025) Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity. J\u00a0Clin Invest 135:e185785","journal-title":"J Clin Invest"},{"key":"5764_CR14","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jaad.2015.08.063","volume":"74","author":"L Gill","year":"2016","unstructured":"Gill\u00a0L, Zarbo\u00a0A, Isedeh\u00a0P et\u00a0al (2016) Comorbid autoimmune diseases in patients with vitiligo: A\u00a0cross-sectional study. J\u00a0Am Acad Dermatol 74:295\u2013302","journal-title":"J Am Acad Dermatol"},{"key":"5764_CR15","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1501a4600","volume":"15","author":"IB Ismail","year":"2025","unstructured":"Ismail\u00a0IB, Bhat\u00a0YJ, Ul Islam\u00a0MS (2025) Treatment Advances in Vitiligo: An Updated Review. Dermatol Pract Concept 15:4600","journal-title":"Dermatol Pract Concept"},{"key":"5764_CR16","doi-asserted-by":"crossref","unstructured":"Klinger T, Augustin M, Baumeister S et\u00a0al. (2026) Epidemiology and Comorbidity of Vitiligo in Germany: A\u00a0Claims 1 Data Analysis. Acta Derm Venereol im Druck","DOI":"10.2340\/actadv.v106.44468"},{"key":"5764_CR17","unstructured":"Krampe J, Leppert B, Melnik S et\u00a0al. (2025) Utilizing Claims Data for Health Service Research: An Examination of Extrapolation Strategies of German SHI Data. In: Deutsche Gesellschaft f\u00fcr Medizinische Informatik, Biometrie und Epidemiologie, editors. 70.\u00a0Jahrestagung der Deutschen Gesellschaft f\u00fcr Medizinische Informatik, Biometrie und Epidemiologie e.\u202fV. (GMDS). Jena, 07.-11. Sept. 2025. D\u00fcsseldorf: German Medical Science GMS Publishing House; 2025. DocAbstr.\u00a091."},{"key":"5764_CR18","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kruger","year":"2012","unstructured":"Kruger\u00a0C, Schallreuter\u00a0KU (2012) A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol 51:1206\u20131212","journal-title":"Int J Dermatol"},{"key":"5764_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jid.2022.10.021","volume":"143","author":"JH Lee","year":"2023","unstructured":"Lee\u00a0JH, Ju\u00a0HJ, Seo\u00a0JM et\u00a0al (2023) Comorbidities in Patients with Vitiligo: A Systematic Review and Meta-Analysis. J\u00a0Invest Dermatol 143:777\u2013789","journal-title":"J Invest Dermatol"},{"key":"5764_CR20","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1007\/s13555-025-01506-y","volume":"15","author":"J Liu","year":"2025","unstructured":"Liu\u00a0J, Matangi\u00a0S, Malempati\u00a0Y et\u00a0al (2025) Prevalence and Association of Autoimmune Comorbidities Among Adults with Vitiligo: A Systematic Literature Review and Meta-analysis of USA-Based Studies. Dermatol Ther (Heidelb) 15:3109\u20133124","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5764_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cytogfr.2024.11.002","volume":"80","author":"K Liu","year":"2024","unstructured":"Liu\u00a0K, Zhou\u00a0L, Shi\u00a0M et\u00a0al (2024) JAK inhibitors in immune regulation and treatment of vitiligo. Cytokine Growth Factor Rev 80:87\u201396","journal-title":"Cytokine Growth Factor Rev"},{"key":"5764_CR22","doi-asserted-by":"crossref","unstructured":"Mientus L, Sommer R, Steinbrink K et al. (2026) Versorgungssituation von Menschen mit Vitiligo - Eine Pilot- und Machbarkeitsstudie zum leitliniengerechten Management in deutschen Hautarztpraxen. Dermatologie (Heidelb) 77:524-530.","DOI":"10.1007\/s00105-026-05729-8"},{"key":"5764_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/CLEP.S304155","volume":"13","author":"N Mohr","year":"2021","unstructured":"Mohr\u00a0N, Petersen\u00a0J, Kirsten\u00a0N et\u00a0al (2021) Epidemiology of Vitiligo - A Dual Population-Based Approach. Clin Epidemiol 13:373\u2013382","journal-title":"Clin Epidemiol"},{"key":"5764_CR24","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.18129","volume":"36","author":"M Picardo","year":"2022","unstructured":"Picardo\u00a0M, Huggins\u00a0RH, Jones\u00a0H et\u00a0al (2022) The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J\u00a0Eur Acad Dermatol Venereol 36:1507\u20131523","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5764_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000275657","volume":"220","author":"MA Radtke","year":"2010","unstructured":"Radtke\u00a0MA, Schafer\u00a0I, Gajur\u00a0AI et\u00a0al (2010) Clinical features and treatment outcomes of vitiligo from the patients\u2019 perspective: results of a national survey in Germany. Dermatology 220:194\u2013200","journal-title":"Dermatology"},{"key":"5764_CR26","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s13555-023-00983-3","volume":"13","author":"D Rosmarin","year":"2023","unstructured":"Rosmarin\u00a0D, Soliman\u00a0AM, Li\u00a0C (2023) Real-World Treatment Patterns in Patients with Vitiligo in the United States. Dermatol Ther (Heidelb) 13:2079\u20132091","journal-title":"Dermatol Ther (Heidelb)"},{"key":"5764_CR27","volume":"15","author":"AH Salama","year":"2023","unstructured":"Salama\u00a0AH, Alnemr\u00a0L, Khan\u00a0AR et\u00a0al (2023) Unveiling the Unseen Struggles: A Comprehensive Review of Vitiligo\u2019s Psychological, Social, and Quality of Life Impacts. Cureus 15:e45030","journal-title":"Cureus"},{"key":"5764_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/jdv.12169","volume":"28","author":"N van Geel","year":"2014","unstructured":"van Geel\u00a0N, Speeckaert\u00a0M, Brochez\u00a0L et\u00a0al (2014) Clinical profile of generalized vitiligo patients with associated autoimmune\/autoinflammatory diseases. J\u00a0Eur Acad Dermatol Venereol 28:741\u2013746","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5764_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jid.2019.06.131","volume":"140","author":"Y Jin","year":"2020","unstructured":"Jin\u00a0Y, Santorico\u00a0S, Spritz\u00a0RA (2020) Pediatric to Adult Shift in Vitiligo Onset Suggests Altered Environmental Triggering. J\u00a0Invest Dermatol 140:241\u2013243.e4","journal-title":"J Invest Dermatol"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05764-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05764-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05764-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:04:17Z","timestamp":1790899457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05764-5"}},"subtitle":["Eine Abrechnungsdatenanalyse zu Pr\u00e4valenz, Komorbidit\u00e4t und Behandlungsmustern","A\u00a0claims data analysis on prevalence, comorbidity, and treatment patterns"],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5764"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05764-5","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0B\u00f6hm erhielt Beratungshonorare von AbbVie, Almirall, Boehringer, Incyte, Johnson & Johnson, MSD, Pfizer sowie Vortragshonorare von AbbVie, Incyte, Isispharma, Johnson & Johnson und Pfizer. A.\u00a0Heuck arbeitet bei AbbVie und k\u00f6nnte AbbVie-Aktien besitzen. M.\u00a0Sebastian kooperierte mit AbbVie, Affibody, Allergan, Alumis, Amgen, Almirall, Apogee, Appolo, AstraZeneca, August Wolff, Boehringer Ingelheim, Bristol Myers Squibb, Dermapharm, Dermira, Incyte, Ipsen, Janssen-Cilag, Johnson & Johnson, LEO Pharma, Lilly, MedImmune, Menlo Therapeutics, Moonlake, MSD, Mundipharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Selection Therapeutics, Takeda und UCB Pharma. L.-M.\u00a0M\u00fcller und A.\u00a0Benson, geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}